Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.45 |
| ▸ | MST1R | Q04912 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 5/20 | 0.41 |
| ▸ | KDR | P35968 | 5/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11886915 | 0.93 | MET (0.47) | METMST1RKDRAXL | |
| SCHEMBL11033882 | 0.92 | BRAF (0.44) | METMST1RIGF1RKDR | |
| SCHEMBL11031908 | 0.90 | MST1R (0.45) | METMST1RIGF1RKDR | |
| SCHEMBL11029810 | 0.89 | MEN1 (0.46) | METMST1RIGF1RKDRAXL | |
| SCHEMBL1161267 | 0.89 | MST1R (0.46) | METMST1RIGF1RKDR | |
| SCHEMBL11029098 | 0.86 | MST1R (0.42) | METMST1RIGF1RKDRAXL | |
| SCHEMBL11030863 | 0.86 | MST1R (0.47) | METMST1RIGF1RKDRAXL | |
| SCHEMBL11026565 | 0.84 | NPC1 (0.46) | METMST1RIGF1RKDR | |
| SCHEMBL14691553 | 0.84 | OPRK1 (0.42) | METHDAC6 | |
| SCHEMBL11050470 | 0.83 | MST1R (0.47) | METMST1RIGF1RKDRAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| EP-2461869-B1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2013-08-21 | — | — | EP | disclosed |
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | CCNC, CCNI, CCNA1 | MET 1111/4885MST1R 2790/4885HDAC6 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.